Evidence map›Paper›PMID 36638900›Full record

ArticleFree radical biology & medicine2023

Characterization of mitochondrial and metabolic alterations induced by trisomy 21 during neural differentiation.

Kendra M Prutton, John O Marentette, Kenneth N Maclean, James R Roede

Open access · greenAbstract read
In one paragraph

Article in Free radical biology & medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Transcriptional consequences of trisomy 21 on neural induction.Frontiers in cellular neuroscience · 2024
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kendra M PruttonDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA; Linda Crnic Institute for Down Syndrome, Aurora, CO, USA.
John O MarentetteDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA; Linda Crnic Institute for Down Syndrome, Aurora, CO, USA.
Kenneth N MacleanLinda Crnic Institute for Down Syndrome, Aurora, CO, USA; Department of Pediatrics, School of Medicine, University of Colorado, Aurora, CO, USA.
James R RoedeDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA; Linda Crnic Institute for Down Syndrome, Aurora, CO, USA. Electronic address: james.roede@cuanschutz.edu.
University of Colorado Anschutz Medical Campus · US

Funding

Xenobiotic Biotransformation in Down SyndromeR01ES027593 · NIEHS · UNIVERSITY OF COLORADO DENVER · PI James R Roede · 2017 to 2026
$5.1M
NIEHS NIH HHS R01 ES027593
6 · The paper itself

Abstract

Cellular redox state directs differentiation of induced pluripotent stem cells (iPSC) by energy metabolism control and ROS generation. As oxidative stress and mitochondrial dysfunction have been extensively reported in Down syndrome (DS), we evaluated mitochondrial phenotypes and energy metabolism during neural differentiation of DS iPSCs to neural progenitor cells (NPCs). Our results indicate early maturation of mitochondrial networks and elevated NADPH oxidase 4 (NOX4) expression in DS iPSCs. DS cells also fail to transition from glycolysis to oxidative phosphorylation during differentiation. Specifically, DS NPCs show an increased energetic demand that is limited in their mitochondrial and glycolytic response to mitochondrial distress. Additionally, DS iPSC and NPC non-mitochondrial oxygen consumption was significantly impacted by NOX inhibition. Together, these data build upon previous evidence of accelerated neural differentiation in DS that correlates with cellular redox state. We demonstrate the potential for mitochondrial and non-mitochondrial ROS sources to impact differentiation timing in the context of DS, which could contribute to developmental deficits in this condition.

Indexed as

Down SyndromeInduced Pluripotent Stem CellsNeural Stem CellsCell DifferentiationHumansMitochondriaReactive Oxygen SpeciesReactive Oxygen Species

Identifiers

PMID36638900
PMCPMC9898228
OpenAlexW4314447472

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.